Reverse Transcriptase

CL-197 is a purine-based nucleoside reverse transcriptase inhibitor (NRTI) that exhibits anti-HIV activity through its selective inhibition of viral reverse transcriptase. This compound has potential applications in studying viral, oncological, and cerebrovascular diseases. Additionally, CL-197 serves as a click chemistry reagent, featuring an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating advanced chemical research.

Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms.

Azvudine is a potent nucleoside reverse transcriptase inhibitor (NRTI) with notable antiviral activity against HIV, HBV, and HCV. It exhibits strong inhibition of HIV-1 and HIV-2, with EC50 values ranging from 0.018 to 6.92 nM, and effectively targets NRTI-resistant strains. Additionally, Azvudine serves as a click chemistry reagent, featuring an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules or those with DBCO or BCN groups, making it suitable for advanced chemical biology applications.

FNC-TP is the intracellular active form of the nucleoside reverse transcriptase inhibitor (NRTI) FNC, targeting reverse transcriptase enzymes. This compound exhibits potent antiviral activity against HIV, HBV, and HCV. Additionally, FNC-TP serves as a versatile click chemistry reagent, featuring an azide group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne, DBCO, or BCN-containing molecules, facilitating advanced research applications in chemical biology.

Lamivudine triphosphate TEA is a potent reverse transcriptase inhibitor that functions by terminating the elongation of viral nucleic acids. It effectively inhibits the reverse transcriptase of HIV and HBV, thereby obstructing viral replication. Additionally, Lamivudine triphosphate TEA targets the RNA-dependent RNA polymerase (RdRp) of the NS5B subunit in HCV, and can be incorporated into the RNA by the RdRp of SARS-CoV-2, interrupting the synthesis and leading to a decrease in mutations in the viral genome. This makes it a critical reagent for research in antiviral therapies and viral replication studies.

Lamivudine salicylate is a nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against HIV reverse transcriptase 1/2 and hepatitis B virus reverse transcriptase. Its oral bioavailability and ability to penetrate the central nervous system make it a valuable compound for anti-viral research. Lamivudine salicylate is widely utilized in studies focused on the treatment and management of HIV and hepatitis B infections.

Lamivudine triphosphate is a potent reverse transcriptase inhibitor that serves as a phosphorylated form of the nucleoside analogue Lamivudine. It effectively disrupts the replication of HIV and HBV viruses through chain termination. Additionally, Lamivudine triphosphate inhibits the RNA-dependent RNA polymerase (RdRp) activity of the NS5B subunit in hepatitis C virus, and can be incorporated into nascent RNA by the SARS-CoV-2 RdRp, thereby preventing mutations in the SARS-CoV-2 RNA. This makes it a valuable reagent for research on viral replication mechanisms and antiviral drug development.

Metacavir is a potent nucleoside reverse transcriptase inhibitor primarily targeting the hepatitis B virus (HBV). This orally active compound exhibits significant antiviral activity, making it a valuable tool in the research of antiviral therapies and the development of treatments for HBV infections. Its specificity and efficacy in inhibiting reverse transcriptase contribute to its potential application in studying hepatitis B and related disorders.

Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor primarily targeting HIV and chronic Hepatitis B. It demonstrates potent antiviral activity by interfering with viral RNA replication, ultimately leading to reduced viral load in infected patients. This compound is essential in research aimed at developing effective therapeutic strategies against retroviral infections.